Skip to main content
Top
Published in: Digestive Diseases and Sciences 8/2022

26-10-2021 | Irritable Bowel Syndrome | Original Article

Opioid-Associated Anorectal Dysfunction in Chronic Constipation

Authors: Nayna A. Lodhia, Laura Horton, Namisha Thapa, Alison H. Goldin, Walter W. Chan

Published in: Digestive Diseases and Sciences | Issue 8/2022

Login to get access

Abstract

Introduction

The role of anorectal and defecatory dysfunction in opioid-related constipation is unclear. We aimed to evaluate the relationship between opioid use and rectal sensation, defecatory function, and balloon expulsion on anorectal physiology testing.

Methods

This was a retrospective cohort study of consecutive adults undergoing high-resolution anorectal manometry (HRAM) at a tertiary center for constipation. Clinical characteristics, medication use, and HRAM findings were obtained. Statistical analyses were performed using Fisher-exact/student t-test for univariate analyses and logistic/general linear regression for multivariable analyses to compare patients with no opioid use, recent (< 3 months) use, and distant (> 3 months) use.

Results

424 patients (49.8 ± 17.2 years; 85.6% female) were included. Compared to those without opioid history, patients with recent use had increased volumes for first rectal sensation (70.4 mL vs 59.4, p = 0.043), urge (120.5 mL vs 101.5, p = 0.017), and maximal tolerance (170.2 mL vs 147.2, p = 0.0018), but not patients with distant use. Recent opioid use was associated with increased risk of dyssynergic defecation (DD) (61.8% vs 46.4%, p = 0.035), but not failed balloon expulsion. On multivariable models controlling for potential confounders, recent opioid use, but not distant use, remained independently correlated with increased volumes for first rectal sensation (β-coefficient 9.78, p = 0.019), urge (β-coefficient 16.7, p = 0.0060), and maximal tolerance (β-coefficient 22.9, p = 0.0032), and higher risk for DD (aOR = 2.18, p = 0.026).

Conclusion

Recent opioid use was an independent risk factor for rectal hyposensitivity and DD on HRAM in patients with constipation, but that effect may decrease with discontinuation of use. Anorectal physiology testing should be considered in patients with opioid-associated constipation.
Literature
20.
go back to reference Vollebregt PF, Hooper RL, Farmer AD, Miller J, Knowles CH, Scott SM. Association between opioid usage and rectal dysfunction in constipation: A cross-sectional study of 2754 patients. Neurogastroenterol Motil 2020:e13839. DOI: https://doi.org/10.1111/nmo.13839. Vollebregt PF, Hooper RL, Farmer AD, Miller J, Knowles CH, Scott SM. Association between opioid usage and rectal dysfunction in constipation: A cross-sectional study of 2754 patients. Neurogastroenterol Motil 2020:e13839. DOI: https://​doi.​org/​10.​1111/​nmo.​13839.
22.
go back to reference Hanson B, Siddique SM, Scarlett Y, Sultan S, American Gastroenterological Association Institute Clinical Guidelines C. American Gastroenterological Association Institute Technical Review on the Medical Management of Opioid-Induced Constipation. Gastroenterology 2019;156(1):229–253 e5. DOI: https://doi.org/10.1053/j.gastro.2018.08.018. Hanson B, Siddique SM, Scarlett Y, Sultan S, American Gastroenterological Association Institute Clinical Guidelines C. American Gastroenterological Association Institute Technical Review on the Medical Management of Opioid-Induced Constipation. Gastroenterology 2019;156(1):229–253 e5. DOI: https://​doi.​org/​10.​1053/​j.​gastro.​2018.​08.​018.
Metadata
Title
Opioid-Associated Anorectal Dysfunction in Chronic Constipation
Authors
Nayna A. Lodhia
Laura Horton
Namisha Thapa
Alison H. Goldin
Walter W. Chan
Publication date
26-10-2021
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 8/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07288-5

Other articles of this Issue 8/2022

Digestive Diseases and Sciences 8/2022 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.